Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"EQRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$100.0 million","newsHeadline":"Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"EQRx","sponsor":"CM Life Sciences","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$2,000.0 million","newsHeadline":"EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"EQRx","sponsor":"Abdul Latif Jameel Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"EQRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Almonertinib

    Menu

    Almonertinib

    DEVELOPMENTS

    INTERMEDIATES

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              EQRx

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting

              Details:

              Aumolertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR- sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR.

              Lead Product(s): Aumolertinib

              Therapeutic Area: Oncology Product Name: EQ143

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EQRx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa

              Details:

              Through the agreement, Abdul Latif Jameel Health will become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.

              Lead Product(s): Aumolertinib

              Therapeutic Area: Oncology Product Name: EQ143

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Abdul Latif Jameel Health

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EQRx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III

              Details:

              Proceeds expand balance sheet to ~$2.0 billion and will be used for “new pharma” platforms. EQRx’s growing pipeline includes two pre-registrational oncology assets that have shown promising Phase 3 data (aumolertinib and sugemalimab), and other clinical-stage programs.

              Lead Product(s): Aumolertinib

              Therapeutic Area: Oncology Product Name: EQ143

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: CM Life Sciences

              Deal Size: $2,000.0 million Upfront Cash: $2,000.0 million

              Deal Type: Merger August 06, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hansoh Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib

              Details:

              Partnership aims to accelerate global access to almonertinib as a treatment for individuals with non-small cell lung cancer (NSCLC).

              Lead Product(s): Aumolertinib

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: EQRx

              Deal Size: Undisclosed Upfront Cash: $100.0 million

              Deal Type: Licensing Agreement July 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY